期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨质疏松症诊疗中应关注的几个问题 被引量：11

下载PDF
导出
摘要 骨质疏松症（osteoporosis，OP）是一种以骨量低下，骨微结构破坏，导致骨脆性增加，易发生骨折为特征的全身性骨病。骨质疏松症起病隐匿，大多数患者并无临床症状，使得早期发现极为困难，当出现骨骼疼痛、体型改变，甚至出现脆性骨骼时往往过了最佳治疗时机。因此，如何早期发现高危人群、早期诊断并选择合理的治疗方案就显得尤为重要。
作者 夏维波 贾觉睿智
机构地区 中国医学科学院北京协和医学院 北京协和医院内分泌科 卫计委内分泌重点实验室
出处 《中国临床医生杂志》 2013年第6期1-2,81,共2页 Chinese Journal For Clinicians
关键词 骨质疏松症 诊疗 早期诊断 骨骼疼痛 骨微结构 临床症状 治疗时机 高危人群
分类号 R58 [医药卫生—内分泌]
  • 相关文献

参考文献15

  • 1Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis [ J ]. Geneva:WHO, 1994,1-129.
  • 2中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南.中华骨质疏松和骨矿盐疾病杂志,2011,:1-10.
  • 3Edwards B J, Hellstein JW, Jacobsen PL, et al. American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs [J]. J Am Dent Assoc, 2008, 139 (12) :1674-1677.
  • 4Arboleya L, Alperi M, Alonso S. Adverse effects of bisphosphonates [J]. ReumatolClin, 2011, 7(3) :189-197.
  • 5Migliorati CA, Epstein JB,Abt E, et al. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review [ J]. Nat Rev Endocrinol, 2011, 7( 1 ) :34-42.
  • 6Khosla S,Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research [J]. J Bone Min Res, 2007, 22(10) :1479-1491.
  • 7Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporo- sis [J]. J Clin Endocrinol Metab, 2010, 95(4) :1555-1565.
  • 8Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking atendronate [ J -. N Engl J Med, 2008, 358(12) :1304-1306.
  • 9Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study [J]. J Bone Miner Res,2009,2d(6) :1095-1102.
  • 10Solomon DH,Patrick A, Brookhart MA. More on reports of esopha- geal cancer with oral bisphosphonate use [ J]. N Engl J Med, 2009, 360(17) :1789-1790.

二级参考文献4

  • 1Lopes RF,Coeli CM,Vaisman M,et al.Additional beneficial effects of recombinant growth hormone in alendronate -treated patients with idiopathic osteoporosis. Endocrine Journal . 2009
  • 2Jacques PB,Robert GJ.For the Scientific Advisory Council of the Osteoporosis Society of Canada 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. JAMC . 2002
  • 3Hodgson SF,Watts NB,Bilezikian JP,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Practice . 2003
  • 4原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量：1837

共引文献25

同被引文献115

引证文献11

二级引证文献140

中国临床医生杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部